ADCT ADC Therapeutics
WatchlistADC Therapeutics News
ABBV.US (ABBV.US) spent $10 billion to acquire Immunogen (IMGN.US) ADC drug developers, and most of the stock prices of drug developers rose
Immunogen closed nearly 83% higher on Thursday and AbbVie closed nearly 3% higher. Shares of other biotech companies developing ADC drugs also rose.
AbbVie-Immunogen Buyout Deal Lifts ADC-focused Biotechs
Analyst Expectations for ADC Therapeutics's Future
Within the last quarter, ADC Therapeutics (NYSE:ADCT) has observed the following analyst ratings: BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings22000Last 30D100001M Ago010002M
HC Wainwright & Co. Maintains Buy on ADC Therapeutics, Lowers Price Target to $3
HC Wainwright & Co. analyst Robert Burns maintains ADC Therapeutics (NYSE:ADCT) with a Buy and lowers the price target from $12 to $3.
Sobi to Present New Data at ASH 2023 Annual Meeting
Sobi will present new data at the 65th Annual Meeting of the American Society of Hematology (ASH) in San Diego from the 9th to the 12th of December...
Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of Its Board of Directors
LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Myricx Bio ('Myricx'), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on
TD Cowen Downgrades ADC Therapeutics to Market Perform
TD Cowen analyst Boris Peaker downgrades ADC Therapeutics (NYSE:ADCT) from Outperform to Market Perform.
Analysts Offer Insights on Healthcare Companies: Akoya Biosciences (AKYA), Paycor HCM (PYCR) and ADC Therapeutics (ADCT)
RBC Capital Maintains Outperform on ADC Therapeutics, Lowers Price Target to $6
RBC Capital analyst Gregory Renza maintains ADC Therapeutics (NYSE:ADCT) with a Outperform and lowers the price target from $7 to $6.
RBC Cuts Price Target on ADC Therapeutics to $6 From $7, Keeps Outperform, Speculative Risk
RBC Cuts Price Target on ADC Therapeutics to $6 From $7, Keeps Outperform, Speculative Risk
Q3 2023 ADC Therapeutics SA Earnings Call
Express News | ADC Therapeutics Sees Continued Decrease In Total Operating Expenses In FY23 And FY24 As Compared to FY22; Expected Cash Runway Into Middle of 2025
ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards
ADC Therapeutics SA (NYSE:ADCT) today announced that on October 10, 2023, it received a notice from the New York Stock Exchange (NYSE) that the Company is not in compliance with the continued listing
ADC Therapeutics Q3 Adj. EPS $(0.41) Beats $(0.63) Estimate, Sales $14.49M Miss $15.99M Estimate
ADC Therapeutics (NYSE:ADCT) reported adjusted quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.63) by 34.92 percent. This is a 415.38 percent decrease over earni
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates
Myricx Expands Its ADC Expertise With the Appointment of Francesca Zammarchi as CSO
LONDON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Myricx Bio ('Myricx'), a UK biotech company focusing on the discovery and development of a completely novel class of selectively cytotoxic payloads for antibody-drug conjugates
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 275 companies made new 52-week lows. Areas of Significance In Today's 52-Week Lows: ARM Holdings (NASDAQ:ARM) was the largest firm by market cap to set a new 52-week low.Tr
Analysts Offer Insights on Healthcare Companies: Werewolf Therapeutics (HOWL), Enanta Pharmaceuticals (ENTA) and ADC Therapeutics (ADCT)
HC Wainwright & Co. Reiterates Buy on ADC Therapeutics, Maintains $12 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates ADC Therapeutics with a Buy and maintains $12 price target.
ADC Therapeutics Tumbles After Withdrawing 2023 Revenue Guidance